CLLS
Cellectis Achieves 100% Overall Response Rate in Phase 1 Data Set for Allogeneic CAR-T Candidate lasme-cel
Cellectis, a biotechnology company pioneering the allogeneic CAR-T approach, has made significant strides in its clinical trials. In its recent Q4 2025 conference call transcript, the company revealed that its allogeneic CAR-T candidate, lasme-cel, achieved a remarkable 100% overall response rate in the target phase 2 population. Speaking at the